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Most patients with ﬁbromyalgia use complementary and alternative medicine (CAM). Properly designed controlled trials are
necessary to assess the eﬀectiveness of these practices. This study was a randomized, double-blind, placebo-controlled, early phase
trial. Fifty patients seen at a ﬁbromyalgia outpatient treatment program were randomly assigned to a daily soy or placebo (casein)
shake. Outcome measures were scores of the Fibromyalgia Impact Questionnaire (FIQ) and the Center for Epidemiologic Studies
Depression Scale (CES-D) at baseline and after 6 weeks of intervention. Analysis was with standard statistics based on the null
hypothesis,andseparationtestforearlyphaseCAMcomparativetrials.Twenty-eight patientscompletedthestudy. Useofstandard
statistics with intent-to-treat analysis showed that total FIQ scores decreased by 14% in the soy group (P = .02) and by 18% in
the placebo group (P < .001). The diﬀerence in change in scores between the groups was not signiﬁcant (P = .16). With the same
analysis, CES-D scores decreased in the soy group by 16% (P = .004) and in the placebo group by 15% (P = .05). The change
in scores was similar in the groups (P = .83). Results of statistical analysis using the separation test and intent-to-treat analysis
revealed no beneﬁt of soy compared with placebo. Shakes that contain soy and shakes that contain casein, when combined with a
multidisciplinary ﬁbromyalgia treatment program, provide a decrease in ﬁbromyalgia symptoms. Separation between the eﬀects
of soy and casein (control) shakes did not favor the intervention. Therefore, large-sample studies using soy for patients with
ﬁbromyalgia are probably not indicated.
1.Introduction
Fibromyalgia syndrome (FMS) is a chronic, generalized pain
syndrome that aﬀects the musculoskeletal system [1]. This
syndrome is typically diagnosed in patients who experience
generalized musculoskeletal pain and have excessive ten-
derness in at least 11 of 18 speciﬁc points [2]. Although
the primary cause of FMS is unclear, a growing body of
evidence indicates that the widespread pain associated with
this syndrome is due to abnormalities in the central nervous
system. Therefore, drug therapy for FMS is most often
aimed at the central nervous system and includes tricyclic
antidepressants, selective serotonin reuptake inhibitors, dual
serotonin andnorepinephrinereuptakeinhibitors,analgesics
and anticonvulsants [1].
In addition to medical therapies, complementary and
alternative medicine (CAM) therapies have been used to
treat FMS symptoms [3]. Overall, >50% of patients with
rheumatologic conditions, including FMS, use CAM ther-
apies [4–6]. Wahner-Roedler et al. [6] reported that 98%
of patients who are referred to a ﬁbromyalgia treatment
program may have used some form of CAM within the2 Evidence-Based Complementary and Alternative Medicine
last 6 months. The types of CAM therapies used to reduce
FMS symptoms include massage, meditation, acupuncture,
hypnotherapyanddietarysupplementation.FewCAMinter-
ventions have been adequately tested in controlled clinical
trials. In a systematic review published in 2003, Holdcraft et
al. [3] concluded that the strongest evidence for eﬃcacy in
FMS exists for acupuncture. Magnesium use, S-adenosyl-L-
methionine(SAMe)use,andmassage therapyhavemoderate
evidence; chlorella use, relaxation, biofeedback, magnet
therapies, homeopathy, botanical oils, balneotherapy and
use of anthocyanidins have limited evidence. In a 2004
published summary of CAM trial data, Ernst [7] concluded
that acupuncture and spinal manipulations have shown a
signiﬁcant promise in the treatment of FMS. No dietary sup-
plement has conclusive evidence of eﬃcacy in the treatment
of FMS symptoms.
Soy is a widely used dietary supplement that has not
been previously tested for treating FMS. On the basis of
studies indicating that dietary soy relieves neuropathic pain
in animals [8–11] and reduces pain and improves range of
motion of the knee joints in humans with osteoarthritis
[12], we hypothesized that soy consumption might improve
FMS symptoms. The aim of our study was to evaluate
whether dietary soy supplement can improve symptoms in
patients with FMS participating in a 1.5-day multidisci-
plinary ﬁbromyalgia treatment program, as measured by the
FibromyalgiaImpactQuestionnaire(FIQ)andtheCenterfor
Epidemiologic Studies Depression Scale (CES-D).
2.Subjectsand Methods
This study was approved by the Mayo Clinic Institutional
Review Board and registered as NCT00279942 in Clinical
Trials.gov.
Patients presenting to the Mayo Fibromyalgia Treatment
Program between May 2006 and August 2006 were invited to
participate in this trial. Exclusion criteria includeddiagnoses
of bipolar disorder, schizophrenia, dementia, diabetes melli-
tus and inﬂammatory bowel disease; allergy to soy or other
study product ingredients; pregnancy; and consumption of
soy products within the past 30 days. Among patients seen
in our Fibromyalgia Treatment Program between May 2006
and August 2006, 117 met the study inclusion criteria and
were invited to participate in the study (Figure 1). Of these,
67 patients declined to participate, and the remaining 50
patients were randomly assigned to either soy supplement or
placebo.
2.1. The Mayo Fibromyalgia Treatment Program. The Mayo
Fibromyalgia Treatment Program is a 1.5 day, multidisci-
plinary outpatient program staﬀed by physicians from the
Department of Physical Medicine and Rehabilitation and
the Department of Rheumatology. Access to this program is
limited to patients with a presumed diagnosis of FMS who
are referred by Mayo Clinic physicians. The patients undergo
an initial evaluation by a registered nurse speciﬁcally trained
in rheumatologic disorders, with the collaboration of a
physician to conﬁrm the diagnosis. Only patients with a
117 Patients met study inclusion
criteria and were invited to
participate in study
67 Declined to
participate
50
Randomly assigned
25
Assigned to
receive soy
25
Assigned to
receive placebo
13 Dropped out of study
3 Had gastrointestinal upset
3 Disliked taste of product
3 Lost to follow-up
2 Lost interest in study
1 Became pregnant
1 Had infection (ﬂu)
9D r o p p e do u to fs t u d y
3 Lost interest in study
2 Disliked taste of product
2 Lost to follow-up
1 Had infection (ﬂu)
1 Lost medications in move
12 Completed study 16 Completed study
Figure 1: Flow chart of patients in the placebo-controlled soy
supplement trial.
conﬁrmed diagnosis of FMS as deﬁned by the American
College of Rheumatology in 1990—namely, widespread
musculoskeletal pain of at least 3 months’ duration and
excessive tenderness in at least 11 of 18 predeﬁned anatom-
ical sites [2]—are enrolled in the program. Components
of the program are carried out by a core group of team
members that includes registered nurses, rheumatologists,
psychiatrists, occupational therapists, physical therapists and
ancillary staﬀ. The mission of the ﬁbromyalgia treatment
program is to improve patients’ physical and mental health
functioning, impartevidence-basedinformationandcreatea
standardized treatment approach. Further details about this
multidisciplinary program have been described [13].
2.2. Study Design. We conducted a randomized, double-
blind, placebo-controlled, early phase trial. Participants were
randomly assigned to either soy supplement or placebo
when they started the ﬁbromyalgia treatment program. An
informed consent was obtained from all participants. The
participants completed the FIQ and the CES-D at baseline
and were randomly assigned to either soy supplement or
placebo taken once a day for 6 weeks. They were asked to
collect wrappers of the product and to send them by mail
in a provided envelope addressed to Mayo Clinic, together
with another set of the completed FIQ and CES-D forms, at
the end of the 6 weeks. The study coordinator, for whom the
assignment of patients was blinded, called the participants
weekly to inquire about product tolerance and compliance.
2.3. Products. The treatment was a soy shake (provided by
Physicians Pharmaceuticals, Inc, Kernersville, NC,USA)that
contained 20g of soy protein and 160mg of soy isoﬂavone.
T h ep l a c e b ow a sas h a k et h a tc o n t a i n e d2 0go fm i l k - b a s e d
protein (casein) and no isoﬂavone (provided by PhysiciansEvidence-Based Complementary and Alternative Medicine 3
Pharmaceuticals, Inc). Flavoring, sweetening and nutritional
content were identical in the two shakes.
2.4. Instruments
2.4.1. Fibromyalgia Impact Questionnaire. The FIQ is a val-
idated questionnaire that was developed to measure status,
progress and outcomes of people with FMS [14]. A self-
administered instrument, it takes ∼5min to complete. The
F I Qc o n t a i n s2 0i t e m st h a tm e a s u r ep h y s i c a lf u n c t i o n i n g ;
symptoms of pain, fatigue, morning tiredness and stiﬀness;
job diﬃculty; depression and anxiety; days of work missed;
and overall well-being of the person during the previous
week. A higher score indicates a greater eﬀect of FMS on the
person, with a range of total score from 0 to 100.
Questions 1 through 11 rate the ability to complete
various activities and are scored and summed to yield 1
physical impairment score (0, no impairment; 10, maximum
impairment).Question12inquiresaboutthenumberofdays
out of the past 7 when the patient felt good, and question
13 inquires about the number of days during the past week
whenthepatientmissedwork,includinghousework,because
of ﬁbromyalgia, with each question yielding a separate score
(0, no impairment; 10, maximum impairment). Questions
14 through 20 are a series of visual analog scales (range, 0–
10)f orra tin gth eva riouss ym pt om sc h a ra ct eris ticofFMS(0,
no impairment; 70, maximum impairment).
2.4.2. Center for Epidemiologic Studies Depression Scale. The
CES-D is a 20-item measure of depression. Its questions
represent depressed mood; feelings of guilt, worthlessness,
helplessness or hopelessness; psychomotor retardation; loss
ofappetite;andsleepdisturbance[15].Scalescorescanrange
from 0 to 60; a higher number indicates greater depression.
Various cutoﬀ points for depression have been used. For
example, Weissman et al. [16]u s e dt h ec u t o ﬀ of 16 and Turk
et al. [17]t h ec u t o ﬀ of 19.
2.5. Statistical Analysis. Patient demographics were summa-
rized using descriptive statistics. The mean (±SD) of the
total FIQ scores and the CES-D scores at baseline and at 6
weeks between the soy group and the placebo group were
analyzed by Wilcoxon rank sum test. The diﬀerence and
relative change (%) of the FIQ and CES-D scores at 6 weeks
from baseline were also compared by Wilcoxon rank sum
test. The comparison of the diﬀerence from baseline to 6
weeks within the soy and placebo groups was analyzed by
the Wilcoxon signed rank test. The analyses were performed
using intent-to-treat and per-protocol approaches. Inintent-
to-treat analysis, a participant who did not complete the
entire 6-week supplement trial or who failed to complete the
FIQ and CES-D forms was considered a dropout.
Because this study was an early phase trial with a small
samplesize,wealsoanalyzedourdatabyusingtheseparation
test, as described by Aickin [18, 19], to assess whether it
is worthwhile to pursue research on soy supplementation
for patients with ﬁbromyalgia. By use of this test, the
standard deviation of the eﬀect estimate (SDE) of the mean
diﬀerence can be found. The value of Δ = 1.645∗ SDE is
then calculated. If the mean diﬀerence exceeds Δ/2 (in the
favorable direction), further research is recommended; if it
decreases below −Δ/2 (in the unfavorable direction), further
research is not recommended. Otherwise, the statement
is made that there is not enough information to make a
recommendation.
3.Results
3.1. Baseline Characteristics. A total of 50 patients (49
women) were recruited for this trial. Median age was
47.7 years (range, 18–76 years). There was no signiﬁcant
diﬀerence in age (P = .99), FIQ scores (P = .36) or CES-
Ds c o r e s( P = .48) between the two groups. Twenty-eight
patients (56%)—12 in the soy group and 16 in the placebo
group (P = .39)—completed the 6-week trial. Reasons for
not completing it are depicted in Figure 1.P a t i e n t sw h o
did not ﬁnish the trial were signiﬁcantly younger (median
age, 39.8 years) than those who ﬁnished it (median age,
53.9 years) (P < .001). The median FIQ score was higher
for patients who did not complete the trial (59.5) than for
those who completed the study (54.8), but the diﬀerence
was not statistically signiﬁcant (P = .12). The median CES-D
score also was higher for patients who did not complete the
trial (26.5) than for patients who completed the trial (14.0),
but this also was not a statistically signiﬁcant diﬀerence
(P = .14).
3.2. Between-Group Comparisons. With intent-to-treat anal-
ysis, the total FIQ scores determined at study entry and at
study completiondecreased 14% (±29) in the soy group and
18%(±25)intheplacebogroup(P = .16).With per-protocol
analysis, the total FIQ scores decreased 29% (±36) in the
soy group and 28% (±26) in the placebo group (P = .93)
(Figure 2). No statistically signiﬁcant decrease between the
soy group and the placebo group was observed for any of the
FIQ subclass scores. With intent-to-treat analysis, the CES-D
scores improved 16% (±26) in the soy group and 15% (±41)
in the placebo group (P = . 8 3 ) ;w i t hp e r - p r o t o c o la n a l y s i s ,
the CES-D scores improved 33% (±30) in the soy group and
24% (±50) in the placebo group (Figure 3). However, the
decrease between the groups was not statistically signiﬁcant
(P = .96). Using various cutoﬀ points for depression (CES-
D ≥ 16, CES-D ≥ 19 and CES-D ≥ 27) and intent-to-
treat analysis, we found a depression rate of 52%, 48% and
28%, respectively, in the soy group and 52%, 48% and 32%
in the control group at study entry. After 6 weeks, these
percentages were 48%, 44% and 24% in the treatment group
and 48%, 36% and 24% in the control group. There was
no statistically signiﬁcant diﬀerence between the groups (P
= 1.00). Determined by using per-protocol analysis for these
three diﬀerentCES-Dscores,thepercentagesofpatientswith
depression at study entry in the treatment group were 42%,
33% and 8% and in the control group were 38%, 38% and
19%. After 6 weeks, 33% of the treatment group had CES-
Ds c o r e so f1 6o rg r e a t e r ,2 5 %h a ds c o r e so f1 9o rg r e a t e r
and 0% had scores of 27 or greater. The percentages for the4 Evidence-Based Complementary and Alternative Medicine
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Figure 2: Total FIQ scores of patients in soy supplement trial,
with intent-to-treat analysis (A–D) and per–protocol analysis (E–
H).Scoreofpatientsrandomlyassignedto receive soyatstudyentry
(A) and score of patients after 6 weeks of soy treatment (B). Score
of patients randomly assigned to receive placebo at study entry
(C) and score of patients after 6 weeks of placebo (D). Score of
patients randomly assigned to receive soy at study entry (E) and
scoreofpatients after 6 weeks of soytreatment (F). Scoreof patients
randomly assigned to receive placebo at study entry (G) and score
of patients after 6 weeks of placebo (H).
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Figure 3: CES-D scores of patients in soy supplement trial, with
intent-to-treat analysis (A–D) and per-protocol analysis (E–H).
Score of patients randomly assigned to receive soy at study entry
(A) and score of patients after 6 weeks of soy treatment (B). Score
of patients randomly assigned to receive placebo at study entry
(C) and score of patients after 6 weeks of placebo (D). Score of
patients randomly assigned to receive soy at study entry (E) and
scoreofpatients after 6 weeks of soytreatment (F). Scoreof patients
randomly assigned to receive placebo at study entry (G) and score
of patients after 6 weeks of placebo (H).
control group were 31%, 19% and 6%, respectively. There
was no statistically signiﬁcant diﬀerence between the groups.
The separation test using the diﬀerence from baseline to
6 weeks showed no beneﬁt for soy, as determined by FIQ
scores and CES-D scores for both intent-to-treat and per-
protocol analyses. We did not have enough information to
makeany recommendation fororagainst theuseof soyusing
the separation test per-protocol analysis based on total FIQ
scores (Table 1).
3.3. Within-Group Comparisons. Signiﬁcant, but modest,
improvement in total FIQ scores (soy group, P = .02; placebo
group,P <.001)(Figure 2) and CES-D scores (soy group, P =
.004; placebo group, P = .05) (Figure 3) between study entry
and study completion was seen in both groups. Using three
diﬀerentcutoﬀpoints for depression (CES-D ≥ 16, CES-D ≥
19 and CES-D ≥ 27), we found no signiﬁcant improvement
using the McNemar test for the soy and control groups (P >
.50).
3.3.1. FIQ Subclass Scores. The average score of answers to
questions 1 through 11 showed no signiﬁcant improvement
from before treatment to after treatment in both groups,
as did the average score of answers to questions 12 and
13. However, the average score of answers to questions 14
through 20 showed signiﬁcant improvement from before
treatment to after treatment in the soy group (P = .004) and
the placebo group (P = .001).
4.Discussion
The present study shows that use of soy product and use
of the chosen placebo for 6 weeks, when combined with an
educational intervention, were both associated with modest
improvement in symptoms of ﬁbromyalgia and depression.
Patients seen in the Mayo Fibromyalgia Treatment Pro-
gram have moderate to severe symptoms, as demonstrated
by the high total FIQ score of our sample at study entry
(average score, 59.4 ± 13.3). A 1.5-day multidisciplinary
treatment program, such as the program developed at our
institution is considered standard care for these patients and
has been shown to have a signiﬁcant positive eﬀect on the
impact of illness among patients with FMS [13]. Despite
participation in such multidisciplinary treatment programs
and use of many conventional medications (e.g., tricyclic
antidepressants, selective serotonin reuptake inhibitors, dual
serotonin and norepinephrine reuptake inhibitors, anal-
gesics, anticonvulsants), most patients with FMS continue to
have functionally limiting symptoms [20].
Soy consumption has been reported in the CAM liter-
ature to have many beneﬁcial eﬀects on bone health, the
cardiovascular system and degenerative arthritis and has
been shown in epidemiologic studies to be associated with
lowerrisk ofseveralcancers[21].Intrigued byanimal studies
indicating that dietary soy provided relief in neuropathic
pain, we decided to perform this early phase trial [8–11].
Using standard statistics based on the null hypothesis, we
show that the use of dietary soy is no more helpful than
the use of casein when each is combined with a brief
multidisciplinary treatment program. Although we cannot
exclude the high drop-out rate, a patient population with
severe symptoms as a result of referral bias, and a lack of
eﬃcacy of the soy product as reasons for these ﬁndings,
another possible cause is the small sample size of our study,
which represents an early phase trial. In concordance withEvidence-Based Complementary and Alternative Medicine 5
Table 1: Summary of data analysis with a separation test a.
Outcome Control (placebo) Treatment (soy)
SDE Δ/2 b Mean
diﬀerence
(placebo/soy)
Separation
in favor of
placebo or
soy c
Further
research
with soy
indicated?
Mean
change in
scores
95% CI
Mean
change in
scores
95% CI
Intent-to-treat analysis
F1-11d −0.51 −3.55 to 2.54 −0.07 −1.93 to 1.79 0.18 0.15 −0.44 Placebo No
F12d −2.06 −8.69 to 4.57 −1.26 −7.00 to 4.48 0.45 0.37 −0.80 Placebo No
F13d −1.12 −7.01 to 4.77 −0.32 −5.08 to 4.44 0.39 0.32 −0.80 Placebo No
F14-20d −8.84 −38.73 to 21.05 −6.56 −29.36 to 16.24 1.91 1.57 −2.28 Placebo No
Total FIQ scores −12.52 −53.34 to 28.29 −8.21 −39.39 to 22.97 2.61 2.15 −4.32 Placebo No
Total CES-D scores −5.12 −31.60 to 21.36 −1.92 −8.12 to 4.28 1.39 1.15 −3.20 Placebo No
Per-protocol analysis
F1-11d −0.79 −4.52 to 2.94 −0.15 −2.89 to 2.59 0.32 0.27 −0.64 Placebo No
F12d −3.22 −10.63 to 4.20 −2.62 −10.16 to 4.92 0.71 0.58 −0.60 Placebo No
F13d −1.75 −8.89 to 5.39 −0.67 −7.63 to 6.29 0.68 0.56 −1.08 Placebo No
F14-20d −13.81 −47.69 to 20.07 −13.67 −40.64 to 13.30 2.95 2.42 −0.15 Neither ... e
Total FIQ scores −19.57 −65.40 to 26.26 −17.10 −55.62 to 21.42 4.06 3.34 −2.47 Neither ...
Total CES-D scores −8.00 −40.05 to 24.05 −4.00 −10.99 to 2.99 2.37 1.95 −4.00 Placebo No
aAs described by Aickin [18, 19]; bΔ/2 = 1.645∗SDE/2; cIf the mean diﬀerence exceeds Δ/2 (in the favorable direction, positive for soy), further research is
recommended; dF1-11, questions1-11of FIQ, which rate the abilityto completevarious activitiesand are scored and summedto yield1 physicalimpairment
score(0,no impairment;10,maximumimpairment);F12,question12ofFIQ, whichinquiresabout thenumberofdaysoutofthepast7dayswhenthepatient
felt well (0, no impairment; 10, maximum impairment); F13, question 13 of FIQ, which inquires about the number of days during the past week when the
patient missed work, including housework, because of ﬁbromyalgia (0, no impairment; 10, maximum impairment); F14-20, questions 14-20 of FIQ, which
are a series of visual analog scales for rating the various symptoms characteristic of FMS (0, no impairment; 70, maximum impairment); eEllipses indicate
not enough information to make a recommendation. CI, conﬁdence interval.
Aickin [18, 19], we believe that early phase research in CAM
is important because of its large inﬂuence on the subsequent
expenditure of money and eﬀort in CAM therapies. By
analyzing our data with separation testing, we were unable
to document any separation between soy use and casein use
(control) through FIQ and CES-D scores in favor of soy
when using intent-to-treat analysis, as well as per-protocol
analysis. Our interpretation of these results is that further
studies using large sample sizes of patients with ﬁbromyalgia
are unlikely to show a positive eﬀect of soy supplement
compared with placebo and therefore are not indicated.
Given the prevalence of CAM, the many various CAM
therapies used for patients with FMS, and the cost associated
with their use, it appears prudentthat each of these therapies
shouldbecarefullyassessed, initially withearlyphasetrials. If
the early phase trials result in promising ﬁndings, adequately
powered clinical trials should be performed.
The results of this randomized, double-blind, placebo-
controlled, early phase trial of soy shakes for patients with
FMS suggests that, on the basis of FIQ scores and CES-D
scores, dietary soy supplementation is no more beneﬁcial
than casein shakes.
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